EC approves Pelmeg: Mundipharma’s answer to chemotherapy-induced neutropenia
Mundipharma, a German pharmaceutical company, has achieved a significant milestone with the European Commission (EC)’s approval of Pelmeg, its pegylated biosimilar to Amgen’s Neulasta (pegfilgrastim). Designed to reduce the duration of neutropenia and associated infections in adults undergoing chemotherapy, Pelmeg provides a cost-effective alternative to traditional treatment options. EU Approval of Pelmeg for Neutropenia The […]